Precision Medicine in Inflammatory Bowel Disease
DOI:
https://doi.org/10.52787/agl.v52i3.245Keywords:
Inflammatory bowel disease, ulcerative colitis, Crohn's disease, biomarkers, precision medicineAbstract
Inflammatory bowel disease (IBD) is a group of chronic disorders of the gastrointestinal tract characterized by phases of inflammatory activity alternating with phases of disease remission. IBD has a course that is difficult to predict, with no tendency to spontaneous cure.1,2 There are 3 main subtypes: Crohn's disease (CD), ulcerative colitis (UC) and colitis not yet classified. In CD the most frequent location is the ileocecal and it usually presents an inflammatory pattern at the beginning that evolves into a stenosing or fistulizing pattern, given its transmural nature, with the need for surgery in up to 80% of patients. UC, limited to the mucosa and submucosa of the colon, usually presents with superficial lesions and extends from the rectum proximally. Unclassified colitis presents features of both entities and it is not possible to define its nature.3
References
-1. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan;11(1): 3-25.
-2. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017 Jun 1;11(6):649-670.
-3. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785-94.
-4. de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):739-749.
-5. Noor NM, Verstockt B, Parkes M, Lee JC. Personalised medicine in Crohn's disease. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):80-92.
-6. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease-algorithm for practical management. Aliment Pharmacol Ther. 2016 Jan;43(1):30-51.
-7. Fine S, Papamichael K, Cheifetz AS. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2019 Dec;15(12):656-665.
-8. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019 May;4(5):341 353.
-9. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008 Feb 23;371(9613):660-667.
-10. Carpio D. Farmacología de la enfermedad inflamatoria intestinal. En: Gomollon F, Hinojosa J, Gassull MA. Enfermedad inflamatoria intestinal. IV Edición. GETECCU
-11. Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol. 2018 Jan 10;11:1756283X17745029.
-12. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington (DC): National Academies Press (US); 2011.
-13. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics 2013;14:55.
-14. Winkler H. Verbreitung und Ursache der Parthenogenesis im Pflanzenund Tierreiche [Distribution and cause of parthenogenesis in plants animal kingdoms]. Jena, Germany: Verlag Von Gustav Fischer; 1920
-15. Pe ina-Šlaus N, Pe ina M. Only one health, and so many omics. Cancer Cell Int 2015;15:64.
-16. Vidal M, Cusick ME, Barabási AL. Interactome networks and human disease. Cell. 2011 Mar 18;144(6):986-98.
-17. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al.; IBDMDB Investigators. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 2019;569:655-62.
-18. Rozich JJ, Holmer A, Singh S. Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2020 Jun;115(6):832-840.
-19. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, et al. Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. Digestion. 2013;87(3):212-21.
-20. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006 Mar;130(3):650-6.
-21. Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, et al. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec;10(12):1385-1394.
-22. Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol. 1987 Feb;9(1):50-4.
-23. Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol. 2004 Nov;19(11):1247-52.
-24. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996 Jun;38(6):905-10.
-25. Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 Feb;15(2):229-239.e5.
-26. Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, et al. Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020 Dec;18(13):2952-2961.e8.
-27. Barré A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:896-905.
-28. Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. Crohns Colitis 2020;14:694-709
-29. Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res 2020;9.
-30. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988 29:990-996
-31. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119-24.
-32. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014;20:91-99.
-33. Nasir BF, Griffiths L, Nasir A, Roberts R, Barclay M, Gearry R, et al. Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. J Clin Gastroenterol. 2013 Mar;47(3):242-5.
-34. Yang SK, Hong M, Zhao W, Jung Y, Tayebi N, Ye BD, et al. Genome-wide association study of ulcerative colitis in Koreans suggests extensive overlapping of genetic susceptibility with Caucasians. Inflamm Bowel Dis 2013,19:954
-35. Juyal G, Negi S, Sood A, Gupta A, Prasad P, Senapati S, et al. Genome-wide association scan in north Indians reveals three novel HLA-independent risk loci for ulcerative colitis. Gut 2015.64:571-579.
-36. Weersma RK, Stokkers PC, van Bodegraven AA, van Hogezand RA, Verspaget HW, de Jong DJ, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut. 2009 Mar;58(3):388-95.
-37. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics. 2002 Jan;3(1):89-98. 38. Donnan JR, Ungar WJ, Mathews M, Rahman P. Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies. Ther Drug Monit. 2011 Apr;33(2):192-9.
-39. Booth RA, Ansari MT, Loit E, Tricco AC, Weeks L, Doucette S, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med. 2011 Jun 21;154(12):814-23, W-295-8.
-40. Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014 Sep;46(9):1017-20.
-41. Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Predictive model for the outcome of infliximab therapy in Crohn’s disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis 2007.13:372-379
-42. Cowen L, Ideker T, Raphael BJ, Sharan R. Network propagation: a universal amplifier of genetic associations. Nat Rev Genet. 2017 Sep;18(9):551-562.
-43. Sedivy JM, Banumathy G, Adamsal PD. Aging by epigenetics - a consequence of chromatin damage? Exp Cell Res. 2008;314:1909-17.
-44. Bird A. Perceptions of epigenetics. Nature. 2007 May 24;447(7143):396-8.
-45. Dige A, Støy S, Rasmussen TK, Kelsen J, Hvas CL, Sandahl TD, et al. Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease. J Crohns Colitis. 2013 Apr;7(3):248-55.
-46. Bogaert S, Laukens D, Peeters H, Melis L, Olievier K, Boon N, et al. Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol. 2010 Dec 13;11:61
-47. McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 2015; 523: 612-16.
-48. Allez M, Auzolle C, Ngollo M, Bottois H, Chardiny V, Corraliza AM, et al. T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence. Gut. 2019 Nov;68(11):1961-1970.
-49. Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, et al. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017 Jul;153(1):77-86.e6.
-50. Schulte L, Beck A, Hofelich J, Reuther HS, Klaus J. Real-Life Ustekinumab Response and Blood Cytokine Profiles in Patients with Crohn’s Disease. Am J Gastroenterol Hepatol. 2020;1(1):1006.
-51. Mateos B, Sáez-González E, Moret I, Hervás D, Iborra M, Cerrillo E, et al. Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. Dig Dis. 2021;39(1):1-9.
-52. Ihara Y, Torisu T, Miyawaki K, Umeno J, Kawasaki K, Hirano A, et al. Ustekinumab Improves Active Crohn's Disease by Suppressing the T Helper 17 Pathway. Digestion. 2021;102(6):946-955.
-53. Sewell GW, Kaser A. Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention. J Crohns Colitis. 2022 May 11;16 (Supplement_2):ii3-ii19.
-54. Sato S, Chiba T, Nakamura S, Matsumoto T. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis. J Gastroenterol Hepatol. 2015 Oct;30(10):1467-72.
-55. Cerrillo E, Moret I, Iborra M, Pamies J, Hervás D, Tortosa L, et al. A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence. Inflamm Bowel Dis. 2019 Sep 18;25(10):1681-1691
-56. Pelczar P, Witkowski M, Perez LG, Kempski J, Hammel AG, Brockmann L, et al. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Science 2016; 354:358-362.
-57. Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, et al. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 2019:129:1910-1925
-58. Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: What is in the Pipeline? J Crohns Colitis. 2022 May 11;16 (Supplement_2):ii64-ii72.
-59. Santos-Antunes J, Nunes AC, Lopes S, Macedo G. The relevance of vitamin D and antinuclear antibodies in patients with inflammatory bowel disease under anti-TNF treatment: a prospective study. Inflamm Bowel Dis 2016; 22:1101-1106
-60. Nguyen DL, Nguyen ET, Bechtold ML. pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD. South Med J 2015;108:139-143.
-61. Verstockt S, Verstockt B, Vermeire S. Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). Expert Opin Ther Targets 2019;23:943-954.
-62. Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, et al. Efficacy and safety of infliximab therapy and predictors of response in korean patients with Crohn’s disease: a nationwide, multicenter study. Yonsei Med J 2016;57:1376-1385.
-63. De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013 Sep;19(10):2111-7.
-64. Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015 May;148(5):938-947.e1.
-65. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004 May 15;19(10):1079-87.
-66. Kolho KL, Korpela K, Jaakkola T, Pichai MV, Zoetendal EG, Salonen A, et al. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. Am J Gastroenterol. 2015 Jun;110(6):921-30.
-67. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146:1489-99.
-68. Choung RS, Princen F, Stockfisch TP, Torres J, Maue AC, Porter CK, et al. Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016 Jun;43(12):1300-10.
-69. Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S, et al. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci. 2012 Nov;57(11):2944-54.
-70. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD detection of complications. J Crohns Colitis. 2019 Feb 1;13(2):144-164.
-71. Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014 Jul;109(7):994-1004.
-72. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000 Apr;118(4):705-13.
-73. Fiocchi C. Inflammatory bowel disease: complexity and variability need integration. Front Med 2018;5:75.
-74. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15;362(15):1383-95.
-75. Guerra I, Chaparro M, Bermejo F, Gisbert JP. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. Curr Drug Metab. 2011 Jul;12(6):594-8.
-76. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun;11(6):654-66.
-77. Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN, et al. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012 Nov;36(9):840-9.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Alejandro Mínguez, Pilar Nos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
